ERBB2 and breast carcinoma: Utilizing DISVT with our machine learning-assisted image analysis platform and pilot human subjects, we demonstrate that EV’s CD24 and EpCAM can be used as biomarkers to detect breast cancer (HER2-positive) at Stages II, III, and IV.